Age-related macular degeneration: The costs to society and the patient

Current Opinion in Ophthalmology

Volumn 18, Issue 3, 2007, Pages 201-205

  Gupta, Omesh P ^a,e   Brown, Gary C ^a,b,c   Brown, Melissa M ^b,c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CENTER FOR VALUE BASED MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e WILLS EYE HOSPITAL   (United States)

Author keywords

Age related macular degeneration; Cost analysis; Cost effectiveness; Direct costs; Indirect costs; Low vision

Indexed keywords

ABSENTEEISM; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; HUMAN; LASER COAGULATION; LIFE EXPECTANCY; MEDICAL ASSESSMENT; MEDICARE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; UNEMPLOYMENT; VISUAL IMPAIRMENT;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HEALTH CARE COSTS; HUMANS; MACULAR DEGENERATION; VISION, LOW;

EID: 34247195487     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32810c8df4     Document Type: Review

References (21)

1. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104:7-21.
2. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106:17-32.
3. Brown MM, Brown GC, Stein JD, et al. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005; 40:277-287.
4. West SK, Rubin GS, Broman AT, et al. How does visual impairment affect performance on tasks of everyday life? The SEE Project. Salisbury Eye Evaluation. Arch Ophthalmol 2002; 120:774-780.
5. Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. Pharmacoeconomics 2006; 24:319-334. The authors provide a comprehensive review that critically evaluates the current literature. Current publications are addressed and potential areas of future research are proposed.
6. Morse AR, Yatzkan E, Berberich B, Arons RR. Acute care hospital utilization by patients with visual impairment. Arch Ophthalmol 1999; 117:943-949.
7. Schmier JK, Halpern MT, Covert D, et al. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration. Retina 2006; 26:1056-1062. Caregiving costs were estimated by patient self-reporting. Substantial differences in costs were related to visual acuity. In patients with poor visual acuity, these costs are a majority of the total healthcare expense.
8. Schmier JK, Halpern MT, Covert DW, et al. Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD). Disabil Rehabil 2006; 28:1331-1337. The direct medical costs of services, supplements, and devices were estimated by patient self-reporting. These cost figures varied widely depending on visual acuity.
9. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119:1417-1436.
10. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004; 88:450-454.
11. Trevithick J, Massel D, Robertson JM, et al. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy? Ophthalmic Epidemiol 2004; 11:337-346.
12. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006; 124:1754-1760. Direct medical costs, other direct costs, and productivity losses are estimated from private insurance and Medicare claims data for four major ocular diseases, including age-related macular degeneration. Direct nonophthalmologic costs, productivity costs, and governmental budgetary impact were only estimated collectively for the four major ocular diseases.
13. Salm M, Belsky D, Sloan FA. Trends in cost of major eye diseases to Medicare, 1991 to 2000. Am J Ophthalmol 2006; 142:976-982. The authors performed a retrospective cohort study to estimate the impact of four major ocular diseases on Medicare payments from 1991 to 2000. The study outlines the trend in direct medical costs of age-related macular degeneration over this time period.
14. Busbee BG, Brown MM, Brown GC, Sharma S. CME review: a cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003; 23:279-287; quiz 443-444.
15. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration: a value-based reappraisal with 5-year data. Am J Ophthalmol 2005; 140:679-687.
16. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004; 88:1107-1112.
17. Sharma S, Bakal J, Sharma SM, et al. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005; 40:369-377.
18. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004; 88:982-987.
19. Tolman J, Hill RD, Kleinschmidt JJ, Gregg CH. Psychosocial adaptation to visual impairment and its relationship to depressive affect in older adults with age-related macular degeneration. Gerontologist 2005; 45:747-753.
20. Eklund K, Sonn U, Nystedt P, Dahlin-Ivanoff S. A cost-effectiveness analysis of a health education programme for elderly persons with age-related macular degeneration: a longitudinal study. Disabil Rehabil 2005; 27:1203-1212.
21. Bonastre J, Le Pen C, Soubrane G, Quentel G. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21:181-190.